Literature DB >> 23090001

Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Fumiaki Ueno1, Toshiyuki Matsui, Takayuki Matsumoto, Katsuyoshi Matsuoka, Mamoru Watanabe, Toshifumi Hibi.   

Abstract

Crohn's disease is a disorder of unknown etiology and complicated pathogenesis. A substantial amount of evidence has accumulated recently and has been applied to clinical practice. The present guidelines were developed based on recent evidence and the formal consensus of experts relevant to this disease. Here we provide an overview of these guidelines, as follows. Target disease: Crohn's disease Users: Clinical practitioners in internal medicine, surgery, gastroenterology, and general practice Purpose: To provide appropriate clinical indicators to practitioners Scope of clinical indicators: Concept of Crohn's disease, epidemiology, classifications, diagnosis, treatment, follow up, and special situations Intervention: Diagnosis (interview, physical examination, clinical laboratory tests, imaging, and pathology) and treatment (lifestyle guidance, drug therapy, nutritional therapy, surgery, etc.) Outcome assessment: Attenuation of symptoms, induction and maintenance of remission, imaging findings, quality of life (QOL), prevention of complications and harm of therapy Methods for developing these guidelines: Described in the text Basis of recommendations: Integration of evidence level and consensus of experts Cost-benefit analysis: Not implemented Evaluation of effectiveness: Yet to be confirmed Status of guidelines: Updated version of the first Guidelines published in 2010 Publication sources: Printed publication available and electronic information in preparation Patient information: Not available Date of publication: October 2011 These guidelines were intended primarily to be used by practitioners in Japan, and the goal of these guidelines is to improve the outcomes of patients with Crohn's disease.

Entities:  

Mesh:

Year:  2012        PMID: 23090001      PMCID: PMC3541931          DOI: 10.1007/s00535-012-0673-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  171 in total

1.  The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire.

Authors:  G A Moody; C Probert; V Jayanthi; J F Mayberry
Journal:  Int J Colorectal Dis       Date:  1997       Impact factor: 2.571

2.  Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark.

Authors:  Tine Jess; Lene Riis; Ida Vind; Karen Vanessa Winther; Sixten Borg; Vibeke Binder; Ebbe Langholz; Ole Østergaard Thomsen; Pia Munkholm
Journal:  Inflamm Bowel Dis       Date:  2007-04       Impact factor: 5.325

3.  Effects of current and former cigarette smoking on the clinical course of Crohn's disease.

Authors:  J Cosnes; F Carbonnel; F Carrat; L Beaugerie; S Cattan; J Gendre
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

4.  Extended strictureplasty for multiple short skipped strictures of Crohn's disease.

Authors:  I Sasaki; Y Funayama; H Naito; K Fukushima; C Shibata; S Matsuno
Journal:  Dis Colon Rectum       Date:  1996-03       Impact factor: 4.585

5.  A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).

Authors:  J F Colombel; M Lémann; M Cassagnou; Y Bouhnik; B Duclos; J L Dupas; B Notteghem; J Y Mary
Journal:  Am J Gastroenterol       Date:  1999-03       Impact factor: 10.864

6.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

Authors:  Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Donny M Chen; Michelle L Pritchard; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05       Impact factor: 11.382

7.  Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas.

Authors:  Toshihiro Sakurai; Toshiyuki Matsui; Tsuneyoshi Yao; Yasuhiro Takagi; Fumihito Hirai; Kunihiko Aoyagi; Mitsuo Okada
Journal:  JPEN J Parenter Enteral Nutr       Date:  2002 Mar-Apr       Impact factor: 4.016

8.  Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study.

Authors:  R C Thirlby; J C Land; L F Fenster; R Lonborg
Journal:  Arch Surg       Date:  1998-08

Review 9.  Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

Authors:  Joel R Rosh; Thomas Gross; Petar Mamula; Anne Griffiths; Jeffrey Hyams
Journal:  Inflamm Bowel Dis       Date:  2007-08       Impact factor: 5.325

10.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-05
View more
  57 in total

1.  Cumulative Inflammation Could Be a Risk Factor for Intestinal Failure in Crohn's Disease.

Authors:  Yoshifumi Watanabe; Norikatsu Miyoshi; Shiki Fujino; Hidekazu Takahashi; Naotsugu Haraguchi; Taishi Hata; Chu Matsuda; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori; Tsunekazu Mizushima
Journal:  Dig Dis Sci       Date:  2019-02-26       Impact factor: 3.199

2.  Possible diagnostic role of antibodies to Crohn's disease peptide (ACP): results of a multicenter study in a Japanese cohort.

Authors:  Keiichi Mitsuyama; Mikio Niwa; Junya Masuda; Hiroshi Yamasaki; Kotaro Kuwaki; Hidetoshi Takedatsu; Teppei Kobayashi; Fukunori Kinjo; Kazuto Kishimoto; Toshiyuki Matsui; Fumihito Hirai; Kazuya Makiyama; Kazuo Ohba; Hiroo Abe; Hirohito Tsubouchi; Hiroshi Fujita; Ryuichiro Maekawa; Hiroshi Yoshida; Michio Sata
Journal:  J Gastroenterol       Date:  2013-12-03       Impact factor: 7.527

Review 3.  Quality of care in Crohn's disease.

Authors:  Govind K Makharia
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

4.  Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial.

Authors:  Hiroko Matsumoto; Satoko Ohfuji; Kenji Watanabe; Hirokazu Yamagami; Wakaba Fukushima; Kazuhiro Maeda; Noriko Kamata; Mitsue Sogawa; Masatsugu Shiba; Tetsuya Tanigawa; Kazunari Tominaga; Toshio Watanabe; Yasuhiro Fujiwara; Yoshio Hirota; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2015-02-12       Impact factor: 7.527

Review 5.  Clinicopathologic features of chronic nonspecific multiple ulcers of the small intestine.

Authors:  Motohiro Esaki; Junji Umeno; Takanari Kitazono; Takayuki Matsumoto
Journal:  Clin J Gastroenterol       Date:  2015-03-19

6.  Evaluation of diagnostic criteria for Crohn's disease in Japan.

Authors:  Takashi Hisabe; Fumihito Hirai; Toshiyuki Matsui; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2013-04-03       Impact factor: 7.527

Review 7.  Similarities and differences between Behçet's disease and Crohn's disease.

Authors:  Veli Yazısız
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

8.  Anorectal fistula is an early manifestation of Crohn's disease that occurs before bowel lesions advance: a study of 11 cases.

Authors:  Naoto Saigusa; Tadashi Yokoyama; Masaru Shinozaki; Ryoji Miyahara; Tsuyoshi Konishi; Toshio Nakamura; Yasuhisa Yokoyama
Journal:  Clin J Gastroenterol       Date:  2013-07-14

9.  Hematologic malignancies in the Japanese patients with inflammatory bowel disease.

Authors:  Norimasa Fukata; Kazuichi Okazaki; Mika Omiya; Mitsunobu Matsushita; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2013-08-19       Impact factor: 7.527

Review 10.  Tools for primary care management of inflammatory bowel disease: do they exist?

Authors:  Alice L Bennett; Pia Munkholm; Jane M Andrews
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.